Skip to main content

Rabbit Monoclonal Amyloid-beta precursor protein antibody. Suitable for WB, I-ELISA, Dot and reacts with Human, Synthetic peptide samples.

Be the first to review this product! Submit a review

Images

Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034), expandable thumbnail
  • Indirect ELISA - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034), expandable thumbnail
  • Dot Blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034), expandable thumbnail

Key facts

Isotype
IgG1
Host species
Rabbit
Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WBI-ELISADotIHC-P
Human
Tested
Tested
Expected
Not recommended
Synthetic peptide
Not recommended
Not recommended
Tested
Not recommended

Tested
Tested

Species
Human
Dilution info
1/1000
Notes

-

Not recommended
Not recommended

Species
Synthetic peptide
Dilution info
-
Notes

-

Tested
Tested

Species
Human
Dilution info
0.0625 µg/mL
Notes

-

Not recommended
Not recommended

Species
Synthetic peptide
Dilution info
-
Notes

-

Tested
Tested

Species
Synthetic peptide
Dilution info
1/2000
Notes

-

Expected
Expected

Species
Human
Dilution info
Use at an assay dependent concentration.
Notes

-

Not recommended
Not recommended

Species
Human, Synthetic peptide
Dilution info
-
Notes

-

Associated Products

Select an associated product type

1 product for Alternative Version

Target data

Function

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed:25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed:17062754, PubMed:23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.

Alternative names

Recommended products

Rabbit Monoclonal Amyloid-beta precursor protein antibody. Suitable for WB, I-ELISA, Dot and reacts with Human, Synthetic peptide samples.

Key facts

Isotype
IgG1
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
IBR-10-2-3
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Pyroglutamate beta amyloid also known by its abbreviation pGlu-Aβ is a modified form of beta amyloid that plays a significant role in the pathology of Alzheimer's disease. This peptide is approximately 40-42 amino acids in length contributing to its molecular mass range of 4 to 5 kDa. Pyroglutamate beta amyloid is generated through a post-translational modification where glutamate residues on beta amyloid undergo cyclization. This modification imparts stability and resistance to degradation causing it to accumulate in the brain. Researchers find pyroglutamate beta amyloid mainly in the neurons and plaques of the brains of Alzheimer’s patients.

Biological function summary

Pyroglutamate beta amyloid affects neuronal function by increasing the aggregation propensity of beta amyloid. It enhances the toxic effects on synapses and neurons disrupting communication and leading to synaptic dysfunction. Pyroglutamate-modified amyloid beta is a component of the amyloid plaque complex which includes other amyloid peptides and metal ions. The presence of pGlu-Aβ in these plaques enhances their stability and neurotoxicity accelerating neuronal degradation and loss of cognitive functions.

Pathways

Modified pyroglutamate beta amyloid involves itself in amyloidogenic pathways that include processes such as the beta-secretase and gamma-secretase pathways. These pathways lead to production and modification of amyloid beta peptide initiating plaque formation in the brain. The interaction of pyroglutamate beta amyloid with tau protein is significant as the aggregation of these proteins advances neurodegeneration. Tau proteins become hyperphosphorylated in response disrupting cellular transport and further promoting Alzheimer's disease progression.

Associated diseases and disorders

Pyroglutamate beta amyloid connects closely with Alzheimer's disease where its modified form accelerates plaque formation and neurodegeneration. Researchers also study its role in frontotemporal dementia another neurodegenerative disorder characterized by tau protein dysfunction. The aggregation of pyroglutamate beta amyloid interacts with other forms of amyloid beta as well as tau contributing to the pathological hallmarks of these disorders.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034), expandable thumbnail

    Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034)

    Blocking and diluting buffer and concentration was 5% NFDM/TBST.

    Lanes 1 - 2: Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034) at 1/1000 dilution

    Lanes 1 - 2: Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab290645) at 1/1000 dilution

    Lane 1: beta Amyloid pE3-42 (aa674-713) peptide 100ng

    Lane 2: beta Amyloid 1-42 (aa672-713) peptide 100ng

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/1000000 dilution

    Exposure time: 3s

  • Indirect ELISA - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034), expandable thumbnail

    Indirect ELISA - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034)

    Indirect ELISA antibody dose-response curve using ab264034 with antigen at 1000 ng/ml

  • Dot Blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034), expandable thumbnail

    Dot Blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034)

    Dot blot analysis of pyroglutamate beta amyloid using ab264034 at 1/2000 dilution, followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100,000 dilution.

    Blocking and diluting buffer and concentration was 5% NFDM/TBST.

    Lane 1: beta Amyloid pE3-42 (aa674-713) peptide

    Lane 2: beta Amyloid 1-42 (aa672-713) peptide

    Exposure time: 3 minutes.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com